Sign in PRO MARKETPLACE SUBSCRIBE

Premium
My Portfolio
My Authors
- My Authors
- Author Email Alerts
Top Stocks
- Ratings Screener
- ETF Screener
Latest News
Markets
Stock Ideas
Dividends
ETFs
Investing Strategy
Watch & Listen
- Podcasts
- Videos

Knowledge Base
Feedback Forum

Equillium (EQ) Investor Presentation - Slideshow

Dec. 4, 2020 4:34 PM ET

|

| About: Equillium, Inc. (EQ)

by: SA Transcripts

The following slide deck was published by Equillium, Inc. in conjunction with this event.

1114

Virtual Investor / Analyst Day

Safe Harbor Statement

Today’s Agenda Speakers

Novel Treatments for Severe Immuno-inflammatory Disorders

Itolizumab Development Strategy

T Cell Mediated Immuno-inflammatory Diseases

Our Journey to Improve Patient Lives...

Potent Immune Modulation

CD6-ALCAM Pathway Central to Immuno-inflammation

CD6 Expression Associated with T Cell Function

CD6 high Cells Exhibit Greater Pathogenic Capacity

CD6 -/-Phenotype of T eff & T reg Cells

CD6-ALCAM Pathway Central to Immuno-inflammation

An Example of the CD6-ALCAM Pathway in Disease

CD6 & ALCAM are Increased in Intestine of

CD6-ALCAM Pathway is Associated with Severity of IBD

CD6 high Cells are Enriched in Inflamed GI Tissues

high

Itolizumab (EQ001) - A First-in-Class Anti-CD6 Antibody

Antigenic Modulation of Cell Surface CD6

CD6 Blockade Inhibits T Activation and Proliferation

CD6 Blockade Inhibits Pathogenic T Activity

CD6 Blockade Inhibits Pathogenic T eff Activity

low

Translational Biology - Summary Tables

Translational Biology - Summary Tables

Upstream, Disease Modifying Immuno-inflammatory Mechanism

Advancing Itolizumab in

8,500 Allo-HSCT’s performed in 2018

aGVHD: Advancing Toward Late-Stage Development in 2021

Acute Graft-versus-Host Disease:

Graft vs. Host Disease Classification

Graft vs. Host Disease

aGVHD Pathogenesis: Three Step Model

Risk Factors for aGVHD

aGVHD: Clinical Features

Cutaneous Acute GVHD

Intestinal Acute GVHD

Liver Acute GVHD

aGVHD Grade/Severity and Survival

aGVHD Severity: Biomarkers

aGVHD Severity: Biomarkers and Outcomes

Prevention Strategies for aGVHD Control

aGVHD: Steroids as Initial Therapy

aGVHD: Initial Steroid Therapy Outcome

Summary: Initial Steroid Dose in aGVHD

Initial Therapy: Additional Agents

History at the Dana Farber- Targeting CD6 for GVHD

Summary

Trial Overview and Results

EQUATE Study for First-line Treatment in aGVHD

EQUATE Study: Representative Population Enrolled

EQUATE Study: Severe/High Risk Population Enrolled

EQUATE Study: Clinically Meaningful Response at Day 29

Rapid and Durable Response with Itolizumab Treatment

Itolizumab Associated with Dose Reduction in Systemic Steroid Use

Interpreting EQUATE: Itolizumab Response Rates in aGVHD

Itolizumab Decreases Cell Surface CD6 in GVHD Patients

Dose Responsive Reduction of CD6 with Itolizumab Treatment

Reduced levels of CD6 Inform Dose Selection

Case Vignette: Patient History

Systemic Corticosteroid Use

Clinical Regulatory Strategy and Lifecyle Considerations

aGVHD Program Summary

Discussion with Dr. John Koreth and Q&A

Itolizumab - a Promising

100,000 Lupus nephritis patients in the U.S.

Advancing a Personalized Medicine Approach in Lupus Nephritis

Multiple Cell Types Underscore LN Immune Pathogenesis

Therapies Hitting a Ceiling in Achieving Complete Reponses

Approaches to Tackling Disease Heterogeneity

Increased Urinary ALCAM in Lupus Nephritis

CD6-ALCAM Expression in Human Lupus Nephritis

CD6 & ALCAM-expressing Cells are Elevated in LN Patients

Efficacy of CD6 Blockade in Murine Models of SLE/LN

CD6 & ALCAM are Over-Expressed in MRL Model of SLE/LN

Role of CD6 in T Cell-driven Systemic Autoimmunity

Treatment with Anti-CD6 mAb Ameliorates Renal Disease

CD6 Blockade Ameliorates Renal Inflammation

CD6 Blockade Improves Extra-Renal Disease and Survival

Soluble ALCAM as a Biomarker of Activity in Lupus Nephritis

ALCAM a Predictive Biomarker in Patients with Active LN

ALCAM Correlates with Disease Across Multiple Ethnicities

Urine Proteome Analysis of Responders vs Non-responders

Treating Lupus Nephritis Tomorrow – Individualized Therapy

Trial Overview and Results

EQUALISE Study in Lupus / Lupus Nephritis

Study in Lupus / Lupus Nephritis (LN)

Subject Demographics – Type A Cohorts

Interim Safety Data Summary - Type A Cohorts 1 – 4 *

Absolute Lymphocyte Counts with Itolizumab Treatment

Lupus Nephritis Program Summary

Itolizumab - a Differentiated

2.6M Severe asthma patients in the U.S.

CD6-ALCAM Implicated Broadly in the Pathogenesis of Asthma

Potential to Address the Full Spectrum of Uncontrolled Asthma

Upregulation of CD6 & ALCAM in Severe Asthma Patients

Upregulation of CD6 & ALCAM in Severe Asthma Patients

CD6-ALCAM in Lung inflammation & Bronchomotor Tone

Translational Data Presented at Key Congress

Key Cytokines in Asthma Upregulate CD6 on ILC2s

CD6 Enhances Contraction of Asthmatic Airways

Trial Overview and Results

EQUIP Study in Uncontrolled Asthma

Asthma Program Summary

Financial and

Biocon License Agreement Highlights

U.S. Intellectual Property Portfolio and Regulatory Exclusivity

Equillium Financial Overview

Closing Remarks

Multiple Catalysts in 2021 Provide Opportunity for Value Creation

Q&A

For More Information

Click to enlarge

Notes:

Follow SA Transcripts and get email alerts

Disagree with this article? Submit your own.

To report a factual error in this article, click here.

Your feedback matters to us!

|

Advertise with Us

|

|

|

|

|

|

|

Market Data Sources

|

© 2020 Seeking Alpha